Researcher
Mourad Gumusboga
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Jan 2003 → Today - Mycobacteriology (Research unit)
Member
From31 Dec 2002 → 16 Apr 2015
Projects
1 - 2 of 2
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without creating more?From1 Oct 2018 → Today
- Institutional strengthening of the Mycobacteria Reference Laboratory (LRM, Bénin) for quality services and better quality of health care for Mycobacteria and other clinical bacteria, at National and Regional Level.From1 Jan 2018 → 31 Dec 2018
Publications
1 - 10 of 22
- Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings(2022)
Authors: Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kayomo Kaswa, Mohamed Anwar Hossain, M Gumusboga, Gabriela Torrea, BC de Jong, Leen Rigouts, Tom Decroo
- Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Authors: A.K.J. Maug, M.A. Hossain, M Gumusboga, Tom Decroo, W Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pages: 84-86 - Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown(2021)
Authors: Armand Van Deun, T Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, M Gumusboga, P De Rijk, Sabira Tahseen, Bouke de Jong, Leen Rigouts
- The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis(2021)
Authors: Beatrice Achan, Benon B. Asiimwe, Moses L Joloba, M Gumusboga, Willy Ssengooba, Freddie Bwanga
- Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis(2021)
Authors: Tom Decroo, Kya Jai, Kya Jai Maug Aung, Mohamed Anwar Hossain, M Gumusboga, Nimer Ortuno-Gutierrez, BC de Jong, Armand Van Deun
- First-line tuberculosis treatment with double-dose rifampicin is well tolerated(2020)
Authors: A.K.J. Maug, M.A. Hossain, M Gumusboga, Tom Decroo, W Mulders, Sofie Braet, Jozefien Buyze, Diana Arango, Céline Schurmans, Natacha Herssens, et al.
Pages: 499-505 - Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes(2020)
Authors: Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, C Uwizeye, M Gumusboga, Tine Demeulenaere, Nimer Ortuno-Gutierrez, Bouke de Jong, Armand Van Deun
- Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements(2020)
Authors: Alberto Piubello, Mahamadou Bassirou Souleymane, Souleymane Hassane-Harouna, Abdourahamane Yacouba, Pauline Lempens, Mourtala Mohamed Assao-Neino, Ibrahim Maman-Lawan, Sala Attaher, Boubacar Moustapha, Alphazazi Soumana, et al.
- Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance(2019)
Authors: Gabriela Torrea, Kamela Charmaine Sy Ng, Armand Van Deun, Emmanuel André, Justine Kaisergruber, Willy Ssengooba, Christel Desmaretz, Siemon Gabriëls, Michèle Driesen, Maren Diels, et al.
- Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring(2018)
Authors: Armand Van Deun, K.J.M. Aung, M.A. Hossain, M. A. H. Salim, M Gumusboga, Bouke de Jong, Tom Decroo
Pages: 1450-1461